Chronic Lymphocytic Leukemia

Treatment of CLL is complicated by the fact that most patients are diagnosed at a later age, with a median age at diagnosis of 72 years. In the United States, 75% of patients with CLL are more than 65 years of age.

Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, comments on the impact of targeted therapies for the treatment of chronic lymphocytic leukemia (CLL).

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses BCR-ABL Ratios in patients with chronic-phase chronic myeloid leukemia

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, but at the same time, America’s medical community should work harder to avoid the screen’s potential pitfalls.

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of chronic lymphocytic leukemia (CLL) in elderly patients.

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with AML.

With the growing knowledge of immune system components, signaling processes, and regulatory networks, cancer immunotherapy has yielded increasingly favorable treatment outcomes.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with CLL who harbor the 17p deletion.

Ibrutinib (Imbruvica) has received an FDA approval to include the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.

John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

Miguel-Angel Perales, MD, from Memorial Sloan-Kettering Cancer Center, discusses the challenges regarding access to bone marrow transplant donors.

Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.

The FDA approval of two anti-CD20 antibodies—ofatumumab (Arzerra) and, just recently, obinotuzumab (Gazyva)—has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Idelalisib is a potent and highly selective PI3K inhibitor that promotes apoptosis in primary cells from patients with different B-cell malignancies. Idelalisib has been shown to affect microenvironmental signaling and cell survival both in vitro and in vivo.

Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.

A combination of rituximab (Rituxan) and the PI3K-delta inhibitor idelalisib was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL).

At the 55th Annual Meeting of the American Society of Hematology (ASH), several trials of ibrutinib both alone and in combination with currently used therapies for patients with chronic lymphocytic leukemia (CLL) were presented.

In patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered inappropriate for fludarabine, the addition of ofatumumab to chlorambucil improves clinical outcomes and is tolerable irrespective of patient age or fitness.

According to preliminary results of a phase I clinical trial, nearly half of patients with relapsed or refractory CLL attained objective responses when treated with IPI-145, an oral inhibitor of PI3K-delta and -gamma.